Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Sep 1;21(125):171-2.
doi: 10.1183/09059180.00004112.

Global effort against rare and orphan diseases

Sergio Harari, Vincent Cottin, Marc Humbert
Editorial

Global effort against rare and orphan diseases

Sergio Harari et al. Eur Respir Rev. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Statement of Interest

S. Harari has relationships with drug companies including Actelion, InterMune and GSK. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. V. Cottin has received fees for speaking from Actelion, Boeringer Ingelheim, GSK and Pfizer, and has participated as investigator to clinical trials sponsored by Actelion, Boeringer Ingelheim, GSK and Pfizer. He has served on advisory boards for Actelion, Bayer, Boeringer Ingelheim, InterMune, Lilly and Novartis. M. Humbert has relationships with drug companies including Actelion, Aires, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, Novartis, Nycomed, Pfizer, Stallergènes, TEVA and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.

References

    1. Harari S, Agostini C. New frontiers for rare pulmonary diseases. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: Suppl. 1, S1–S3. - PubMed
    1. Harari S, Agostini C. Proceedings of the 3rd International Congress on Rare Pulmonary Diseases and Orphan Drugs Milan, Italy. Respir Med 2010; 104: Suppl. 1, S1–S92. - PubMed
    1. Caminati A, Cavazza A, Sverzellati N, et al. . An integrated approach in diagnosis of smoking-related interstitial lung diseases. Eur Respir Rev 2012; 21: 207–217. - PMC - PubMed
    1. O'Callaghan DS, Humbert M. A critical analysis of survival in pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 218–222. - PMC - PubMed
    1. Glasgow CG, El-Chemaly S, Moss J. Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 196–206. - PMC - PubMed

Publication types